TABLE 2.
Ever-resistant analysis
| Parameter | Total [n (%)] | No. (%) mupirocin susceptible (n = 194) | No. (%) mupirocin resistant (n = 55) | Univariate OR (95% CIb) | P value | Multivariate ORc (95% CI) | P value |
|---|---|---|---|---|---|---|---|
| Demographic factorsa | |||||||
| Female sex | 115 (46.18) | 88 (45.36) | 27 (49.09) | 1.162 (0.638–2.115) | 0.624 | ||
| Additional dermatologic diagnosis | 79 (31.73) | 60 (30.93) | 19 (34.55) | 1.179 (0.625–2.221) | 0.611 | ||
| Atopic dermatitis | 138 (55.42) | 100 (51.55) | 38 (69.09) | 2.101 (1.111–3.975) | 0.022 | 11.454 (1.986–66.066) | 0.006 |
| Immunosuppression | 9 (3.63) | 4 (2.07) | 5 (9.09) | 4.725 (1.223–18.249) | 0.024 | 17.142 (1.302–225.727) | 0.031 |
| History of mupirocin use | 89 (35.74) | 41 (21.13) | 48 (87.27) | 25.589 (10.778–60.752) | <0.001 | 51.571 (13.720–193.841) | <0.001 |
| Outpatient | 238 (95.58) | 188 (96.91) | 50 (90.91) | 0.319 (0.094–1.089) | 0.068 | 0.087 (0.011–0.663) | 0.018 |
| Zip code group | |||||||
| Mid- and Lower Manhattan (ZCG 1) | 51 (20.48) | 47 (24.23) | 4 (7.27) | 1 | 1 | ||
| Brooklyn, Queens, Long Island, and Staten Island (ZCG 2) | 42 (16.87) | 32 (16.49) | 10 (18.18) | 3.672 (1.059–12.733) | 0.04 | 1.277 (0.218–7.490) | 0.787 |
| Upper Manhattan and the Bronx (ZCG 3) | 75 (30.12) | 53 (27.32) | 22 (40.00) | 4.877 (1.567–15.181) | 0.006 | 7.971 (1.555–40.851) | 0.013 |
| Connecticut and Northern New York State (ZCG 4) | 37 (14.86) | 27 (13.92) | 10 (18.18) | 4.352 (1.244–15.226) | 0.021 | 4.201 (0.756–23.343) | 0.101 |
| New Jersey (ZCG 5) | 41 (16.47) | 32 (16.49) | 9 (16.36) | 3.305 (0.937–11.657) | 0.063 | 3.065 (0.494–19.030) | 0.229 |
| Primary diagnosis | |||||||
| Atopic dermatitis (group 1) | 92 (36.95) | 66 (34.02) | 26 (47.27) | 1 | 1 | ||
| Dermatitis NOS (group 2) | 42 (16.87) | 40 (20.62) | 2 (3.64) | 0.127 (0.029–0.564) | 0.007 | 0.506 (0.049–5.201) | 0.567 |
| Impetigo (group 3) | 36 (14.46) | 30 (15.46) | 6 (10.91) | 0.508 (0.189–1.362) | 0.178 | 1.844 (0.336–10.115) | 0.481 |
| Folliculitis, pustulosis, abscess (group 4) | 34 (13.65) | 26 (13.40) | 8 (14.55) | 0.781 (0.313–1.947) | 0.596 | 1.035 (0.216–4.961) | 0.966 |
| Epidermolysis bullosa (group 5) | 16 (6.43) | 5 (2.58) | 11 (20.00) | 5.585 (1.768–17.645) | 0.003 | 13.037 (1.468–115.739) | 0.021 |
| Other (group 6) | 29 (11.65) | 27 (13.92) | 2 (3.64) | 0.188 (0.042–0.848) | 0.03 | 0.170 (0.010–2.849) | 0.218 |
| Culture site | |||||||
| Head | 69 (27.71) | 58 (29.90) | 11 (20.00) | 0.586 (0.283–1.215) | 0.151 | ||
| Nares | 36 (14.46) | 22 (11.34) | 14 (25.45) | 2.670 (1.259–5.661) | 0.01 | ||
| Trunk | 19 (7.63) | 14 (7.22) | 5 (9.09) | 1.286(0.442–3.741) | 0.645 | ||
| Extremity | 106 (42.57) | 74 (38.14) | 32 (58.18) | 2.256 (1.227–4.149) | 0.009 | 2.782 (0.967–8.003) | 0.058 |
| Skin fold | 90 (36.14) | 69 (35.57) | 21 (38.18) | 1.119 (0.603–2.077) | 0.722 | ||
| Unspecified | 5 (2.01) | 4 (2.06) | 1 (1.82) | 0.880 (0.096–8.035) | 0.91 | ||
| Strain characteristics | |||||||
| MRSA | 36 | 21 (10.82) | 15 (27.27) | 3.089 (1.464–6.517) | 0.003 | ||
| Additional strain(s) | 31 (12.45) | 23 (11.86) | 8 (14.55) | 1.265 (0.532–3.011) | 0.594 | ||
| Amt of bacterial growth | |||||||
| Few | 72 (29.88) | 63 (33.33) | 9 (17.31) | 1 | 1 | ||
| Moderate | 109 (45.23) | 82 (43.39) | 27 (51.92) | 2.305 (1.012–5.248) | 0.047 | 4.030 (1.122–14.475) | 0.033 |
| Many | 60 (24.90) | 44 (23.28) | 16 (30.77) | 2.545 (1.032–6.279) | 0.043 | 1.699 (0.430–6.721) | 0.45 |
a
The mean ages were 4.77 years (mupirocin-susceptible group) and 7.86 years (mupirocin-resistant group); univariate OR (95% CI), 1.123 (1.060–1.190; P < 0.001; n = 249.
b
CI, confidence interval.
c
For the multivariate analysis, variables trimmed from the backward model selection are excluded, and only variables selected for the final model are shown.